MedTrace Logo

Detection of Familial Hypercholesterolaemia in Cardiovascular Disease Registry

NCT02778646 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1622948

Last updated 2016-05-20

No results posted yet for this study

Summary

Familial hypercholesterolaemia (FH) is an autosomal dominant somatic mutation commonly located on the LDL-receptor, APOB, and PCKS9 gene. The estimated prevalence of homozygous FH is estimated at 1 in a million, whereas the prevalence of heterozygous FH ranges from 1/500-1/200 (0.2-0.5%) of the general population. The majority of individuals suffering from FH remain undiagnosed and without treatment. Using preexisting clinical guidelines, this study scored patients within national cardiovascular disease (CVD) registries for FH with the aim of evaluating prevalence of FH among individuals suffering from premature cardiac events within the UK.

Following scoring of the registry, this study also examined the relationship between cholesterol and survival after a premature event in order to understand the possible ramifications of untreated FH on patient survival.

Conditions

  • Familial Hypercholesterolemia
  • Cardiac Event
  • Percutaneous Coronary Intervention

Sponsors & Collaborators

  • Aegerion Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • University College, London

    lead OTHER

Principal Investigators

  • Joy Ayemoba, MSc · UCL

  • John Deanfield, MD · UCL

  • Owen Nicholas, PhD · UCL

  • Riyaz Patel, MD · UCL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2014-12-31
Completion
2014-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02778646 on ClinicalTrials.gov